Apnimed, Inc.
APMDHealthcare|Biotechnology|US
$15.10
+0.94 (+6.64%)
About
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Stock Price
-5.6%(1Y)
1M
-17.1%
3M
-44.1%
6M
-5.6%
YTD
-5.6%
1Y
-5.6%
3Y
-5.6%
5Y
-5.6%
Pipeline Summary
19 total trials2
Phase 1
15
Phase 2
4
Phase 3
0
Phase 4
Completed: 17Unknown: 1By Invitation: 1
Key Facts
Market Cap$628.6M
Employees81
CEOKevin R. Lind
IPO DateJul 29, 2026
Beta7.95
52-Week Range$13.88 – $35.29
Avg Volume492,112
ExchangeNASDAQ
Websiteapnimed.com
Ownership
Float8.1%
Shares Outstanding41.6M
Recent Insider Trades
Morningside Venture Investments LtdBUY
Aug 3, 2026312,500 shares @ $16.00
Morningside Venture Investments LtdCONVERSION
Aug 3, 20266,840,213 shares
Morningside Venture Investments LtdJ
Aug 3, 20266,840,213 shares
Morningside Venture Investments LtdCONVERSION
Aug 3, 202675,624 shares @ $14.40
Morningside Venture Investments LtdJ
Aug 3, 202675,624 shares
Peers
INSPInspire Medical Systems, Inc.
$1.85BNYXHNyxoah S.A.
$86.1MRecent News
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Nov 5, 2026 · globenewswire.com
Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026
Oct 12, 2026 · globenewswire.com
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Oct 2, 2026 · globenewswire.com
Apnimed, Inc. (NASDAQ:APMD) Stock Short Interest Jumps 55.7%
Oct 1, 2026 · defenseworld.net
Apnimed, Inc. (NASDAQ:APMD) Given Consensus Rating of “Moderate Buy” by Brokerages
Sep 22, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 03:55 AM